Hussein Sultan
YOU?
Author Swipe
View article: CNS-derived Tregs regulate peripheral immune responses 4272
CNS-derived Tregs regulate peripheral immune responses 4272 Open
Description The CNS is isolated from the periphery by barriers and is believed to lack immune responses. The lymphatic system links CNS peptides to the dura mater, where antigen-presenting cells activate T cells in the meninges. In this st…
View article: EXPERIMENTAL INVESTIGATION OF THE PERFORMANCE OF VORTEX TUBE SYSTEM USED FOR CONTROL PANELS COOLING
EXPERIMENTAL INVESTIGATION OF THE PERFORMANCE OF VORTEX TUBE SYSTEM USED FOR CONTROL PANELS COOLING Open
To meet the urgent need for effective cooling solutions in a manufacturing setting, the effectiveness of a vortex tube system for cooling electrical control panels is carefully investigated in this experimental study. This paper presents a…
View article: Supplementary Table 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Supplementary Table 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
Reactive T-cell receptors utilized in the study.
View article: Supplemental Figure 3 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Supplemental Figure 3 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
CA-STAT5 induces effector memory in CD8 T cells expanded by TriVax.
View article: Supplemental Figure 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Supplemental Figure 1 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
CD8 T cells transduced with RV express gp100-TCR and CA-STAT5.
View article: Supplemental Figure 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Supplemental Figure 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
RV-transduced T cells expand in an antigen-dependent manner.
View article: Data from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Data from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
Adoptive cell therapy (ACT) using retrovirally transduced T cells represents a promising strategy for enhancing antitumor responses. When used with TriVax, a peptide vaccination strategy, this approach synergistically expands antigen-speci…
View article: Supplementary Table 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition
Supplementary Table 2 from STAT5 Activation Enhances Adoptive Therapy Combined with Peptide Vaccination by Preventing PD-1 Inhibition Open
Key Resources Table
View article: Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S6 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S6: Characterization of antigen-specific CD8+ T cells in MC38 tumors.
View article: Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S3: Biodistribution of cytokine fusion molecules in tumor-bearing mice.
View article: Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S9 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S9: scRNAseq analysis of MC38 tumors.
View article: Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S5 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
View article: Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S2: In vitro culture of human CD8+ T cells, evaluation of CD8α and CD8β expression, and cytokine release assessment.
View article: Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S1: CD8+ T cells drive anti-tumor activity but NK cells are responsible for toxicity with not-α-IL2 therapy.
View article: Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S10 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S10: In vitro and in vivo activity of AB248 in cynomolgus monkey.
View article: Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S4 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S4: Further characterization of CD8-mIL2 activity in mouse tumor models.
View article: Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S2 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S2, Antibodies used in this study
View article: Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S1 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S1, Molecules used in this study
View article: Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Table S3 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Table S3, Single-cell RNA sequencing reagents used in this study
View article: Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S8 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S8: Differential expression by treatment.
View article: Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity
Supplementary Figure S7 from IL2 Targeted to CD8<sup>+</sup> T Cells Promotes Robust Effector T-cell Responses and Potent Antitumor Immunity Open
Supplementary Figure S7: Sub-clustering of naïve-like/recently activated cluster and characterization of clonal expansion and antigen.
View article: Table S1 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S1 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Peptide inclusion list for PRM. Related to “Mass Spectrometry by PRM” in Methods.
View article: Table S15 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S15 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Twenty-two I-Ab binding F244 neoantigens screened.
View article: Table S13 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S13 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Major 1956 and F244 neoantigens.
View article: Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Top 20 predicted H-2Db restricted neoepitopes of 1956 sarcomas.
View article: Figure S7 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Figure S7 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
F244 MHC-I and -II neoantigen prediction and screens.
View article: Table S15 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S15 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Twenty-two I-Ab binding F244 neoantigens screened.
View article: Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S11 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Top 20 predicted H-2Db restricted neoepitopes of 1956 sarcomas.
View article: Table S14 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Table S14 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Top 33 predicted F244 MHC-I neoepitopes.
View article: Figure S3 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry
Figure S3 from Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry Open
Optimal FAIMS CV(s) improve the coverage of I-Ab restricted peptides.